Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms

Published:2018-04-28 Issue:9 Volume:24 Page:1978-1991
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Leber Andrew¹,Hontecillas Raquel¹,Zoccoli-Rodriguez Victoria¹,Bassaganya-Riera Josep¹

Affiliation:

1. Landos Biopharma Inc, Blacksburg, VA

Funder

Virginia Biosciences Health Research Corporation

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/9/1978/26499515/izy167.pdf

Reference55 articles.

1. Inflammatory bowel disease 2017: innovations and changing paradigms;Colombel;Gastroenterology,2017

2. The global burden of IBD: from 2015 to 2025;Kaplan;Nat Rev Gastroenterol Hepatol,2015

3. Drug development in IBD: from novel target identification to early clinical trials;Danese;Gut,2016

4. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age;Yajnik;Adv Ther,2017

5. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease;Vande Casteele;Gastroenterology,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat;International Immunopharmacology;2024-10

2. Nuclear transport of phosphorylated LanCL2 promotes invadopodia formation and tumor progression of glioblastoma by activating STAT3/Cortactin signaling;Journal of Advanced Research;2024-03

3. Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells;Oncology Reports;2024-01-08

4. New Insights into the LANCL2-ABA Binding Mode towards the Evaluation of New LANCL Agonists;Pharmaceutics;2023-12-12

5. Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease;Inflammatory Bowel Diseases;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3